Hyperkalemia in Heart Failure with Reduced Ejection Fraction Implications and Management (2025) Craig J. Beavers

Description

This review examines the challenges of hyperkalemia management in patients with Heart Failure with Reduced Ejection Fraction (HFrEF) who are receiving guideline-directed medical therapies (GDMT) such as RAASi and steroidal mineralocorticoid receptor antagonists (sMRAs). It emphasizes the importance of regular potassium monitoring, the role of comorbidities like chronic kidney disease and diabetes, and the potential benefits of combining therapies like SGLT2 inhibitors to reduce hyperkalemia risk while optimizing HF outcomes.